Managers / Q4 2020 · view latest →
Essex Woodlands Management, Inc.
CIK 0001542339 · 21 WATERWAY AVE, STE 150, THE WOODLANDS, TX, 77380 · 281-364-1555
Summary
Essex Woodlands Management, Inc. reported $385M in U.S.-listed holdings across 8 positions for Q4 2020.
The portfolio is heavily concentrated: MDXG alone accounts for 46.1% of reported value.
Compared with Q3 2020, the fund opened 2 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 94.3% · $363M
- Other · 5.7% · $22M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MDXGMIMEDX GROUP, INC. | NEW | +19.48M | 19.48M | +$178M | $178M |
| EYPTEYEPOINT PHARMACEUTICALS INC | NEW | +4.19M | 4.19M | +$28M | $28M |
| PSDVUSDEYEPOINT PHARMACEUTICALS INC | SOLD OUT | −41.91M | 0 | −$22M | $0 |
| ELGXEURENDOLOGIX INC | SOLD OUT | −125.7K | 0 | −$3,000 | $0 |
| AXGNAXOGEN INC | HELD | +0 | 1.98M | +$12M | $35M |
| RVNCEURREVANCE THERAPEUTICS INC | HELD | +0 | 3.34M | +$11M | $95M |
| VENUS CONCEPT, INC. | HELD | +0 | 12.42M | −$7M | $21M |
| TELATELA BIO, INC. | HELD | +0 | 1.48M | −$2M | $22M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MDXGMIMEDX GROUP, INC.history → | COM | 46.09% | $178M | 19.48M |
| 2 | RVNCEURREVANCE THERAPEUTICS INChistory → | COM | 24.58% | $95M | 3.34M |
| 3 | AXGNAXOGEN INChistory → | COM | 9.21% | $35M | 1.98M |
| 4 | EYPTEYEPOINT PHARMACEUTICALS INChistory → | COM NEW | 7.16% | $28M | 4.19M |
| 5 | TELATELA BIO, INC.history → | COM | 5.76% | $22M | 1.48M |
| 6 | VENUS CONCEPT, INC. | COM | 5.57% | $21M | 12.42M |
| 7 | 4875MEDICINOVA INChistory → | COM NEW | 1.51% | $6M | 1.11M |
| 8 | CATALYST BIOSCIENCES INC | COM NEW | 0.13% | $496,000 | 78.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $251M | 5 | May 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $318M | 6 | Feb 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $307M | 6 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $279M | 6 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $347M | 6 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $433M | 7 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $350M | 7 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $307M | 7 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $345M | 7 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $404M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $113M | 6 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $173M | 7 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $179M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $242M | 7 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $242M | 9 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $414M | 9 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $445M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $451M | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $677M | 9 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $640M | 9 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $385M | 8 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $188M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $204M | 8 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $155M | 8 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $214M | 8 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $161M | 6 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $173M | 6 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $201M | 8 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $251M | 8 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.